Results 301 to 310 of about 121,553 (350)

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Designer Drugs

2022
Neelambika Revadigar, Ching Tary Yu, Isabelle Silverstone-Simard   +2 more
openaire   +1 more source

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Grace M Choong, Grace D Cullen, Ciara C O'sullivan   +2 more
exaly  

Drug-receptor interactions and drug design

Trends in Pharmacological Sciences, 1988
openaire   +2 more sources

Innovations in research and clinical care using patient‐generated health data

Ca-A Cancer Journal for Clinicians, 2020
H S L Jim, Aasha I Hoogland, Naomi C Brownstein   +2 more
exaly  

Current recommendations and recent progress in endometrial cancer

Ca-A Cancer Journal for Clinicians, 2019
Gini F Fleming
exaly  

Recent progress in pancreatic cancer

Ca-A Cancer Journal for Clinicians, 2013
Christopher L Wolfgang, Daniel A Laheru, Elliot Fishman   +2 more
exaly  

Designer drugs.

Texas medicine, 1989
Designer drugs are synthetic analogs of substances with known psychoactive properties. These analogs are dangerous due to their direct pharmacological effects and the presence of toxic by-products that occur during synthesis. Three groups of designer drugs are reviewed (fentanyl, meperidine, and methamphetamine analogs), and their psychoactive effects ...
openaire   +1 more source

Hodgkin lymphoma: A review and update on recent progress

Ca-A Cancer Journal for Clinicians, 2018
Satish P Shanbhag, Richard F Ambinder
exaly